The concept of a brain microbiome has emerged in recent years, challenging long-held beliefs about the brain’s isolation from other body systems. Various studies have hinted at the presence of microorganisms in the brain, indicating their potential role in brain function and disease. The discovery of the brain microbiome opens avenues for exploring novel therapeutic approaches for neurological disorders such as Alzheimer’s.
Recognizing the growing prevalence of neurological disorders, the Union Health Ministry in India has established a national task force dedicated to devising comprehensive strategies for surveillance, prevention, and treatment. The task force aims to address the disparities and inequalities in brain healthcare access based on socio-economic factors, age, location, and gender. It will recommend measures to strengthen the healthcare system and enhance the quality and accessibility of brain healthcare services at all levels.
The HDAC inhibitors market has witnessed significant growth in recent years, driven by the promising therapeutic potential of these drugs in treating a wide range of diseases, particularly cancer and neurological disorders. HDAC inhibitors are a class of compounds that modulate gene expression by inhibiting the activity of histone deacetylases (HDACs), which in turn plays a crucial role in regulating gene expression. This regulatory mechanism has led to the exploration of HDAC inhibitors as potential therapeutic agents for various diseases, with a focus on oncology and neurology.
To address the rising prevalence of neurological disorders in India, the Union Health Ministry has announced plans to offer neurological care at Ayushman Arogya Mandirs, the government’s primary healthcare centres. A National Task Force on Brain Health has been established to provide guidance on the necessary infrastructure and amenities. The task force will focus on improving accessibility, quality, and rehabilitation services for patients with neurological conditions. The World Health Organization estimates that over three billion people worldwide are living with a neurological condition, highlighting the urgency of addressing this issue.
The global radiopharmaceuticals market is projected to grow at a CAGR of 10.22% from 2023 to 2027, according to Technavio. This growth is primarily attributed to the increasing prevalence of neurological disorders, rising demand for early and accurate disease diagnosis, and advancements in medical imaging technologies. Radiopharmaceuticals play a vital role in the diagnosis and treatment of various diseases, including cancer, cardiovascular diseases, and neurological disorders. The market is expected to witness significant growth due to the increasing adoption of personalized medicine, the development of new radiopharmaceuticals, and the expansion of the geriatric population.
Researchers at the University of Cologne have discovered a novel use for Cnicin, an extract from the blessed thistle plant. Animal models and human cells have shown that Cnicin significantly accelerates axon (nerve fiber) growth, offering potential for treating nerve injuries. The study, published in Phytomedicine, highlights the oral administration method as a key advantage of Cnicin.
